RxDoctor Payments Data

Melissa Hixson

Family · Cleveland, TNNPI 1912464447

Payments from drug & device makers

$6,554in general payments, 2019–2025

Across 333 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$825
  • Amgen$663
  • Actelion Pharmaceuticals US, Inc.$453
  • Boston Scientific$416
  • E.r. Squibb & Sons, L.L.C.$375
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,40498%
  • Education$1502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,554 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$12,265
Medicare patients
117
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan195$174,316
EliquisApixaban158$163,107
XareltoRivaroxaban30$31,229
BrilintaTicagrelor22$18,740
JardianceEmpagliflozin13$10,813
Ranolazine ErRanolazine90$10,707
CorlanorIvabradine Hcl14$7,803
Atorvastatin Calcium200$1,932
Isosorbide Mononitrate ErIsosorbide Mononitrate124$1,638
ClopidogrelClopidogrel Bisulfate167$1,477
Potassium Chloride68$1,268
Rosuvastatin Calcium110$1,243
Digoxin50$1,048
Amiodarone Hcl14$1,037
Propafenone Hcl21$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,144$174,316195 claims
PfizerEliquis$254$163,107158 claims
Johnson & JohnsonXarelto$201$31,22930 claims
AstraZenecaBrilinta$317$18,74022 claims
Boehringer IngelheimJardiance$163$10,81313 claims
AmgenCorlanor$663$7,80314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →